Amneal Pharmaceuticals (AMRX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.21 (+2.39%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Amneal Pharmaceuticals (AMRX)
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Key Insights

Critical company metrics and information
  • Share Price

    $8.53
  • Market Cap

    $2.64 Billion
  • Total Outstanding Shares

    309.84 Million Shares
  • Total Employees

    7,700
  • Dividend

    No dividend
  • IPO Date

    May 7, 2018
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.amneal.com

Historical Stock Splits

If you bought 1 share of AMRX before August 26, 2013, you'd have 0.04 shares today.
Execution DateSplit Amount
August 26, 20131-for-25 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-78.63 Million
Exchange Gains/Losses$58000.00
Net Cash Flow From Financing Activities$-251.42 Million
Net Cash Flow, Continuing$-17.20 Million
Net Cash Flow From Operating Activities, Continuing$312.84 Million
Net Cash Flow From Operating Activities$312.84 Million
Net Cash Flow From Investing Activities$-78.63 Million
Net Cash Flow From Financing Activities, Continuing$-251.42 Million
Net Cash Flow$-17.26 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income Tax Expense/Benefit$23.32 Million
Basic Earnings Per Share$0.86
Research and Development$182.53 Million
Operating Expenses$759.67 Million
Net Income/Loss Available To Common Stockholders, Basic$-184.45 Million
Diluted Average Shares$328.54 Million
Benefits Costs and Expenses$2.80 Billion
Operating Income/Loss$187.73 Million
Other Operating Expenses$120.38 Million
Costs And Expenses$2.80 Billion
Income/Loss From Continuing Operations After Tax$-146.48 Million
Net Income/Loss$-146.48 Million
Basic Average Shares$331.46 Million
Income/Loss From Continuing Operations Before Tax$-123.16 Million
Net Income/Loss Attributable To Parent$-179.73 Million
Revenues$2.68 Billion
Preferred Stock Dividends And Other Adjustments$4.73 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$4.73 Million
Cost Of Revenue$1.73 Billion
Nonoperating Income/Loss$-310.88 Million
Selling, General, and Administrative Expenses$456.75 Million
Net Income/Loss Attributable To Noncontrolling Interest$37.98 Million
Diluted Earnings Per Share$0.85
Gross Profit$947.39 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Assets$1.95 Billion
Other Current Liabilities$795.31 Million
Current Assets$1.51 Billion
Other Non-current Liabilities$5.15 Million
Wages$64.90 Million
Intangible Assets$780.19 Million
Long-term Debt$2.39 Billion
Equity Attributable To Noncontrolling Interest$135000.00
Liabilities$3.49 Billion
Equity$-93.57 Million
Other Non-current Assets$736.48 Million
Assets$3.46 Billion
Current Liabilities$1.10 Billion
Temporary Equity$59.89 Million
Accounts Payable$235.00 Million
Liabilities And Equity$3.46 Billion
Inventory$596.36 Million
Equity Attributable To Parent$-93.43 Million
Noncurrent Liabilities$2.40 Billion
Fixed Assets$431.02 Million
Other Current Assets$916.93 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.